88.18
전일 마감가:
$89.65
열려 있는:
$89.62
하루 거래량:
13.78M
Relative Volume:
1.08
시가총액:
$153.59B
수익:
$45.13B
순이익/손실:
$6.28B
주가수익비율:
24.57
EPS:
3.5895
순현금흐름:
$7.38B
1주 성능:
-3.17%
1개월 성능:
+4.54%
6개월 성능:
-29.71%
1년 성능:
-35.38%
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
ABT
Abbott Laboratories
|
88.18 | 153.59B | 45.13B | 6.28B | 7.38B | 3.5895 |
|
SYK
Stryker Corp
|
312.20 | 119.69B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
MDT
Medtronic Plc
|
80.20 | 102.97B | 36.36B | 4.84B | 5.43B | 3.7212 |
|
BSX
Boston Scientific Corp
|
46.91 | 69.72B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
85.11 | 49.01B | 6.30B | 1.07B | 1.09B | 1.8406 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-22 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | 개시 | The Benchmark Company | Buy |
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
How Investors May Respond To Abbott (ABT) Dividend And CE Mark For Dual Glucose‑Ketone Sensor - Yahoo Finance
Can S&P 500 Healthcare Giant Abbott Boost Growth With Libre Duo? - Kalkine Media
How Investors Are Reacting To Abbott (ABT) Pairing Libre Duo Launch With Its Latest Dividend Approval - simplywall.st
Over 100 Organizations Thank America’s Blood Donors on World Blood Donor Day - GlobeNewswire Inc.
Abbott Laboratories (ABT): One of the Best Bargain Stocks to Buy in June - Insider Monkey
Abbott Laboratories Stock (US0028241000): Quiet trading day keeps healthcare name in focus - AD HOC NEWS
Is Abbott (ABT) the Best Longevity Stock to Buy Now? - Insider Monkey
Abbott Laboratories (ABT) Announces Quarterly Dividend of $0.63 - GuruFocus
Abbott Laboratories declares $0.63 dividend - MSN
Abbott Laboratories stock underperforms Friday when compared to competitors - MarketWatch
Abbott Laboratories Keeps Quarterly Dividend at $0.63 a Share, Payable Aug. 17 to Holders of Record as of July 15 - marketscreener.com
Abbott declares 410th consecutive quarterly dividend - PR Newswire
Abbott recalls heart device monitoring system due to malfunction risk - Cardiovascular Business
Abbott Laboratories Stock (US0028241000): Valuation metrics in focus for S&P 500 healthcare name - AD HOC NEWS
Abbott Laboratories Stock 12‑Month Price Target Cut to $115.5, Implies 29% Upside - TradingView
BofA Adjusts Price Target on Abbott Laboratories to $102 From $120 - marketscreener.com
Abbott Laboratories seen as strong buy with 21.8–39.4% upside amid undervaluation and growth prospects. - Pluang
Abbott Laboratories (ABT) Stock Valuation Check After Recent Mixed Performance - simplywall.st
Abbott Laboratories $ABT Shares Bought by Parnassus Investments LLC - MarketBeat
IFM Investors Pty Ltd Has $45.53 Million Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Remains Structurally Undervalued (NYSE:ABT) - Seeking Alpha
Abbott Labs is heavily oversold, says Powers Advisory Group's Matt Powers - MSN
Elfun Trusts Exits Abbott Laboratories, Impacting Portfolio by -1.97% - GuruFocus
Smithbridge Asset Management Inc. DE Raises Holdings in Abbott Laboratories $ABT - MarketBeat
Illinois Municipal Retirement Fund Has $28.27 Million Holdings in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Sold by Dorsey & Whitney Trust CO LLC - MarketBeat
Better medical device stock right now: Abbott Laboratories vs. Dexcom - MSN
This is Why Abbott Laboratories (ABT) is One of the Best Deep Value Stock to Invest In - Yahoo Finance
Abbott Offered Faulty Health Plan Option, Ex-Worker Says - Law360
Abbott Diabetes And Cancer Milestones Contrast With Prolonged Share Price Weakness - Yahoo Finance
Abbott (ABT) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Abbott Laboratories stock underperforms Wednesday when compared to competitors - MarketWatch
symbol__ Stock Quote Price and Forecast - CNN
Abbott office in Easton part of multi-state portfolio sale - The Business Journals
Abbott Laboratories Hit With Lawsuit Over Healthcare Costs (1) - Bloomberg Law News
Abbott Defeats Account Manager’s Sexualized Workplace Claim - Bloomberg Law News
Mounting Evidence Backs Abbott's Cancer Diagnostics Growth Story - Yahoo Finance
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
LPL Financial LLC Has $271.74 Million Stock Position in Abbott Laboratories $ABT - MarketBeat
BSX, MDT Top Abbott Laboratories Stock on Price & Potential - Trefis
Abbott Laboratories $ABT Shares Purchased by Deutsche Bank AG - MarketBeat
Abbott Laboratories: A Better Than 5 Years AgoBut Still Not A Buy - Seeking Alpha
3 Large Cap Defensive Dividend Stocks With Underestimated Payout Power - simplywall.st
New Investors: 3 Rock-Solid Stocks to Build Your Portfolio Around - The Motley Fool
Abbott (ABT) Secures CE Mark for World’s First Dual Glucose‑Ketone Sensing Technology for Diabetes - Insider Monkey
Abbott Laboratories stock (US0028241000): New filing, modest gain, and valuation focus - AD HOC NEWS
Abbott Laboratories stock (US0028241000): analysts stay positive as new diabetes data and steady gai - AD HOC NEWS
Abbott Laboratories price gives in to negative pressureForecast today09-06-2026 - Economies.com
Rep. Rick W. Allen Sells Abbott Laboratories (NYSE:ABT) Stock - MarketBeat
ABT DCF Analysis: Intrinsic Value $93 vs Price $90 - GuruFocus
Wells Fargo Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $109 - Moomoo
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):